KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cvs Health (CVS) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Cvs Health (CVS) over the last 17 years, with Q4 2025 value amounting to $2.32.

  • Cvs Health's EPS (Weighted Average and Diluted) rose 7709.92% to $2.32 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4, marking a year-over-year decrease of 6185.29%. This contributed to the annual value of $1.39 for FY2025, which is 6202.19% down from last year.
  • Per Cvs Health's latest filing, its EPS (Weighted Average and Diluted) stood at $2.32 for Q4 2025, which was up 7709.92% from -$3.13 recorded in Q3 2025.
  • Over the past 5 years, Cvs Health's EPS (Weighted Average and Diluted) peaked at $2.32 during Q4 2025, and registered a low of -$3.13 during Q3 2025.
  • Its 5-year average for EPS (Weighted Average and Diluted) is $1.04, with a median of $1.44 in 2024.
  • Per our database at Business Quant, Cvs Health's EPS (Weighted Average and Diluted) surged by 16756.76% in 2023 and then crashed by 457142.86% in 2025.
  • Over the past 5 years, Cvs Health's EPS (Weighted Average and Diluted) (Quarter) stood at $1.04 in 2021, then skyrocketed by 70.19% to $1.77 in 2022, then fell by 10.17% to $1.59 in 2023, then fell by 17.61% to $1.31 in 2024, then surged by 77.1% to $2.32 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at $2.32 for Q4 2025, versus -$3.13 for Q3 2025 and $0.8 for Q2 2025.